Seoul, South Korea

Hyeung-Geun Park

USPTO Granted Patents = 5 



Average Co-Inventor Count = 7.5

ph-index = 2

Forward Citations = 32(Granted Patents)


Company Filing History:


Years Active: 2002-2020

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Hyeung-Geun Park: Innovator in Metabolic Disease Treatment

Introduction

Hyeung-Geun Park is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of metabolic diseases. With a total of 5 patents, his work has garnered attention for its innovative approaches to health and wellness.

Latest Patents

Among his latest patents is a pharmaceutical composition for preventing or treating metabolic diseases, which includes a stereoisomer of isonitramine or its derivatives. This composition is designed to alleviate conditions such as obesity, diabetes, and hyperlipidemia by inhibiting fat content and promoting insulin secretion. Another notable patent involves novel compounds that act as vanilloid receptor antagonists. These compounds are aimed at treating a variety of ailments, including pain, migraine, and inflammatory diseases.

Career Highlights

Hyeung-Geun Park has worked with Amorepacific Corporation, a leading company in the beauty and health industry. His experience in this organization has allowed him to apply his innovative ideas in practical settings, contributing to advancements in health-related products.

Collaborations

Throughout his career, Hyeung-Geun Park has collaborated with notable individuals such as Young-Ho Park and Young-Ger Suh. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.

Conclusion

Hyeung-Geun Park's contributions to the pharmaceutical industry highlight his dedication to improving health outcomes through innovative solutions. His patents reflect a commitment to addressing significant health challenges, particularly in metabolic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…